Victoza 6 mg Pens for sale
Victoza 6 mg Pens for sale. Victoza® (liraglutide) is a weight loss injection for the patients with diabetes mellitus type 2. Discounts available.
About Victoza
Victoza 6 mg Pens for sale. Victoza (liraglutide) is considered an injectable incretin mimetic, that is a relatively new drug used for the treatment. of type 2 diabetes.
It is commonly recommended for adults and children over the age of 10 with type 2 diabetes to be used in conjunction with diet and lifestyle modifications in order to improve glycaemic control.
Incretin mimetics have been proven to be effective in lowering blood glucose and through clinical research studies, they have also shown to be beneficial for weight loss when compared to subjects on the placebo, when used in combination with diet and exercise.
The FDA first approved Victoza for medical use in adults with type 2 diabetes in 2010 followed by approval in 2019 for the use in children older than 10 years with type 2 diabetes. It has become the only non-insulin drug approved by the FDA to be used in the paediatric population since metformin was approved for pediatric use in 2000.
How is blood glucose levels regulated in our body?
Glucose is the body’s primary source of energy and in fact the obligatory source of energy for the adult brain; cells use glucose and fatty acids along with amino acids for cellular metabolism. The need to maintain adequate fuel supplies in the face of intermittent food intake and variable metabolic demands is fulfilled by careful balance between the 2 main glucose regulating hormones; insulin and glucagon. Insulin is the main hormone controlling intermediary metabolism, having its main actions on liver, fat and muscle. It is an anabolic hormone: its overall effect is to conserve fuel by facilitating the uptake and storage of glucose, amino acids and fats after a meal. Its most striking acute effect is to lower blood glucose. When we eat in excess, the excessive calories are stored as glycogen in the liver and muscle or fat in adipose tissue. During fasting, these energy stores need to be mobilized in a regulated manner.
Insulin is secreted by ? cells located in the Islets of Langerhans in the pancreas. Many factors stimulate insulin secretion, but the main one is blood glucose. Incretins, especially GIP and GLP-1 secreted, respectively, by K and L cells in the gut are also important.
Insulin has essential metabolic actions as a fuel storage hormone and also affects cell growth and differentiation. It decreases blood glucose by:
• Increasing glucose uptake into muscle and fat / adipose tissue via Glut-4
• Increasing glycogen synthesis
• Decreasing gluconeogenesis • Decreasing glycogen breakdown.
What is Diabetes?
Diabetes mellitus is a chronic metabolic disorder in which persistent hyperglycaemia is caused by deficient insulin secretion or by resistance to the action of insulin. This leads to the abnormalities of carbohydrate, fat and protein metabolism that are characteristic of diabetes.
Mechanism of action of Victoza
Victoza / Liraglutide is a functional analogue of the incretin hormone glucagon-like peptide-1 (GLP-1), an incretin analogues / mimetic. Aside from boosting insulin secretion, they have other actions which offer potential advantages over other insulin secretagogues in diabetes:
• Reducing post-prandial glucagon secretion
• Slowing gastric emptying • Reducing food intake by enhancing satiety (a feeling of fullness) by way of acting on GLP-1 receptors in the brain
• Increase ?-cell mass
• Animal studies suggest that there may be a stimulatory effect of GLP-1 analogues on beta cell mass although this has not yet been demonstrated reliably in humans.
Consequently, weight gain and postprandial hyperglycaemia are reduced, and HbA1c levels decline. It also has proven to reduce the incidence of cardiovascular events such as stroke and heart diseases
Dose and administration
Liraglutide is administered as a subcutaneous injection, initially 0.6 mg once daily for at least 1 week, then increased to 1.2 mg once daily for at least 1 week, then increased if necessary to 1.8 mg once daily twice or once daily. Dose of concomitant insulin or sulfonylurea may need to be reduced if these drugs are administered together.
A Victoza pen contains 18mg of liraglutide in 3mL of solution and the pen pen delivers three ranges of doses (0.6 mg, 1.2 mg and 1.8mg).
Side effects Victoza 6 mg Pens for sale
Victoza can cause mild or serious side effects. The following list depicts subset of side effects that you will experience while taking Victoza. However, this does not contain all possible side effects. Talk with your doctor or pharmacist for more information on the potential side effects of Victoza.
Common side effects
• Nausea (the most common side effect)
• Vomiting
• Constipation
• Diarrhoea
Uncommon side effects
• Malaise
• Pancreatitis (Inflammation of the pancreas)
Patients should be advised to discontinue and immediately contact their health care provider if symptoms of acute pancreatitis occur, such as persistent, severe abdominal pain.
